Urgent.News

What's breaking now, across thousands of outlets.

More in Health & Medicine

Hanmi Drugs Show Promise in Phase 1 Trials

Hanmi Pharmaceutical said two next-generation anticancer drug candidates under development demonstrated both antitumor activity and safety in global Phase 1 clinical trials.

  • Hanmi's HM97662 and BH3120 showed promise in Phase 1 trials.
  • HM97662 targets EZH1 and EZH2 proteins to suppress gene expression.
  • BH3120 is an immuno-oncology candidate with positive liver toxicity results.

More from Tuesday 17 November →